Multinational pharmaceutical and diagnostics company OPKO Health has signed a definitive agreement to acquire Cytochroma. Under the purchase, OPKO intends to include Cytochroma's Replidea and Alpharen, which are in Phase 3 clinical trials ...
Tags: OPKO Health, Cytochroma, CKD, pharmaceutical
Cytochroma has announced termination of a license agreement with Mitsubishi Tanabe Pharma (MTPC) thereby regaining rights to all indications of lunacalcipol indications in the US and in Asian territories. The companies mutually decided to ...
Tags: Cytochroma, Mitsubishi Tanabe Pharma, lunacalcipol indications
Cytochroma, a clinical stage specialty pharmaceutical company, has selected OmniComm Systems' eClinical Suite of applications for its two Phase III studies. OmniComm's eClinical Suite, including the EDC, CTMS, Safety, and Coding ...
Tags: Cytochroma, clinical stage, eClinical Suite, patient data, adverse events